|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide polymorphisms (SNPs) of PROC and PROS1 may be closely associated with DVT in this thrombophilia family.
|
31295762 |
2019 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders.
|
31064749 |
2019 |
|
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
TF, TFPI, and APC had the same variation characteristics in the DVT subgroup compared with the no DVT subgroup.
|
29196248 |
2018 |
|
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
We aimed to identify new diagnostic biomarkers for DVT and to investigate their relationship with hypercoagulability markers [D-dimer and activated protein C-protein C inhibitor (APC-PCI) complex].
|
29672822 |
2018 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Rare mutations in PROC, PROS1 or SERPINC1 as well as common variants in F5, F2, F11 and SERPINC1 have been identified as risk factors for deep vein thrombosis (DVT).
|
26982741 |
2016 |
|
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
CTD_human |
Compound heterozygous protein C deficiency in a family with venous thrombosis: Identification and in vitro study of p.Asp297His and p.Val420Leu mutations.
|
25748729 |
2015 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The other mutations of Leu-34Pro and Thr295Ile with reduced PC activity and antigen levels were identified in Proband 2, a 19-year-old male with DVT.
|
25393254 |
2014 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Women carrying the factor V Leiden (F5 rs6025) polymorphism, or who had reduced sensitivity to activated protein C (aPC) in the absence of F5 rs6025, had increased risk for DVT, with unadjusted ORs 7.7 (95% CI 4.7-12.7) and 3.5 (95% CI 2.2-5.4), respectively.
|
23015030 |
2012 |
|
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Genetic deficiencies of PROS1, PROC, and SERPINC1 (antithrombin) are risk factors for deep vein thrombosis (DVT).
|
18954896 |
2009 |
|
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
The efficiency of a new prothrombin-based activated protein C (APC) resistance test to detect factor V Leiden (FVL) was clinically evaluated in 150 Italian patients with deep venous thrombosis.
|
17890946 |
2007 |
|
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
CTD_human |
Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.
|
12730085 |
2003 |
|
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
None of the patients with normal APC response and not receiving thalidomide developed DVT.
|
11943931 |
2002 |
|
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Complexes between activated protein C and protein C inhibitor measured with a new method: comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis.
|
11776306 |
2001 |
|
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
We aimed to evaluate a new APC resistance test, on the basis of the procoagulant activity present in one snake venom of a crotalidae family: STA Staclot APC-R. We studied 36 consecutive patients with an acute deep venous thrombosis (DVT) confirmed by compression ultrasonography and carrying the FV:Q506 allele, assessed by DNA analysis, 103 of their family members and 35 consecutive patients with a proven DVT but who did not carry the FV:Q506 allele.
|
9690807 |
1998 |
|
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
It has been demonstrated that the most common coagulation defect predisposing to venous thrombosis, resistance to activated protein C (APC), is not associated with an increased risk for pulmonary embolism, but the evidence was based on a functional assay to diagnose APC resistance and no information about concomitant deep vein thrombosis was provided.
|
9065990 |
1997 |
|
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Resistance to activated protein C (APC-R) is at present considered the most frequent laboratory abnormality in patients with deep vein thrombosis.
|
8899255 |
1996 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We investigated the sensitivity to APC in 180 Japanese controls and in 96 Japanese patients with venous and arterial thrombosis (28 with deep vein thrombosis; 13 with pulmonary thromboembolism; 41 with cerebral infarction; and 14 with coronary artery disease).
|
8732627 |
1996 |
|
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Resistance to activated protein C (APC) is at present considered the most frequent laboratory abnormality in patients with deep-vein thrombosis.
|
8547095 |
1995 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Recently it was found that the anticoagulant response to APC (APC resistance) was very weak in the plasma of 21% of unselected consecutive patients with thrombosis and about 50% of selected patients with a personal or family history of thrombosis; moreover, 5% of healthy individuals show APC resistance, which is associated with a sevenfold increase in the risk for deep vein thrombosis.
|
8164741 |
1994 |
|
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|